Premium
Atypical pharmacokinetics of atazanavir in an HIV‐1‐infected patient
Author(s) -
Cattaneo Dario,
Meraviglia Paola,
Cozzi Valeria,
Baldelli Sara,
Milani Greta,
Clementi Emilio
Publication year - 2012
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.2010.00905.x
Subject(s) - atazanavir , therapeutic drug monitoring , pharmacokinetics , tolerability , medicine , drug , trough concentration , pharmacology , human immunodeficiency virus (hiv) , pharmacogenetics , bioequivalence , ritonavir , antiretroviral therapy , intensive care medicine , virology , viral load , adverse effect , chemistry , genotype , biochemistry , gene
An HIV‐infected patient with very low atazanavir (ATV) plasma trough concentrations despite clinical signs of poor drug tolerability was described. By therapeutic drug monitoring (TDM), the authors found that the patient had an atypical ATV pharmacokinetics characterized by rapid drug absorption followed by very fast drug clearance probably attributable to his genetic background. This case underlines the importance of traditional and pharmacogenetic‐based TDM for the individualization of ATV therapy in HIV‐1 patients.